FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, namely oncology and may be used for treating multiple myeloma in a patient recurrent after bortezomib or refractory therapy. That is ensured by administering a VEGF antagonist representing a VEGF antibody (bevacizumab). What is also presented is a method of treating multiple myeloma recurrent after alkylating agent therapy.
EFFECT: group of inventions provides the effectiveness of the VEGF antibody for suppression of bortezomin sensitive and/or resistant tumours.
48 cl, 10 dwg, 2 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW SYNERGETIC EFFECTS | 2009 |
|
RU2471499C2 |
| METHOD OF TREATING MULTIPLE MYELOMA | 2009 |
|
RU2519750C2 |
| IMPROVED METHODS FOR TREATING TUMOURS | 2007 |
|
RU2481853C2 |
| TREATMENT OF B-CELLULAR MALIGNANT TUMORS USING ANTI-CD40L ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES AND/OR BY CHEMOTHERAPY AND RADIOTHERAPY | 2000 |
|
RU2305561C2 |
| COMBINED THERAPY WITH TYPE II ANTI-CD20 ANTIBODIES IN COMBINATION WITH PROTEASOME INHIBITOR | 2008 |
|
RU2520757C2 |
| APPLICATIONS OF IMMUNOCONJUGATES WITH CD138 AS TARGET | 2010 |
|
RU2561041C2 |
| USING ANTI-CD20 TYPE II ANTIBODY, HAVING HIGH ANTIBODY-INDUCED CELL-DEPENDENT CYTOTOXICITY (ADCC), COMBINED WITH CYCLOPHOSPHAMIDE, VINCRISTINE AND DOXORUBICIN FOR TREATING NON-HODGKIN LYMPHOMAS | 2009 |
|
RU2589704C2 |
| METHODS OF TREATING CANCER USING APILIMOD | 2016 |
|
RU2738934C2 |
| APLIDINE FOR TREATMENT OF MYELOMA | 2004 |
|
RU2335294C2 |
| COMPOSITIONS COMPRISING ANTIBODY TO CD38 AND CARFILZOMIB | 2014 |
|
RU2670127C2 |
